Early Methylene Blue for Septic Shock

Methylene blue (MB) is a selective inhibitor of inducible nitric oxide synthase (iNOS) and soluble guanylate cyclase (sGC), two downstream mediators involved in the pathologic vasodilation seen in septic shock. By inhibiting excess nitric oxide signaling, MB can theoretically help restore vascular tone. Historically, MB has been used as a rescue therapy in refractory vasoplegia, particularly after cardiopulmonary bypass. Early randomized trials in sepsis suggested some benefit, but they were small and underpowered. A larger trial of a non-selective nitric oxide inhibitor was terminated early due to increased mortality, leading to a pause in research for nearly two decades. More recent observational data and a 2022 meta-analysis have revived interest in MB as a vasopressor-sparing agent.

This randomized controlled trial evaluated whether early administration of methylene blue (MB) could shorten the duration of vasopressor support in adult patients with septic shock. Ninety-one patients were enrolled at a single academic ICU in Mexico and randomized within 24 hours of starting norepinephrine. Patients received either MB (100 mg IV over 6 hours daily for 3 days) or placebo. All patients were managed using a standardized sepsis protocol, including fluid responsiveness assessments, vasopressin initiation, and continuous hydrocortisone infusion. Primary outcome was time to complete vasopressor discontinuation, defined as 48 hours off all vasopressors. Secondary outcomes include vasopressor-free days at day 28, length of ICU and hospital stay, lactate trends, mechanical ventilation duration, and safety outcomes.

Key Findings

• Primary Outcome
• Time to vasopressor discontinuation was significantly shorter in the MB group: 69 hours vs 94 hours (p < 0.001), a median reduction of 25 hours.
• Secondary Outcomes
• Patients who received MB had one additional vasopressor-free day at 28 days (p = 0.008).
• ICU length of stay was reduced by 1.5 days (6.6 vs 7.9 days; p = 0.039), and hospital stay was shortened by 2.7 days (9.0 vs 10.5 days; p = 0.027).
• The 28-day mortality rate was lower in the MB group (33% vs 46%), although this difference did not reach statistical significance (p = 0.23).
• Importantly, there were no serious adverse effects. The most common finding was green-blue urine discoloration (seen in 93% of MB patients), and mild methemoglobinemia (median 2.9%, well below toxic thresholds).

Author Conclusion

The authors concluded that early adjunctive methylene blue safely reduced vasopressor duration and length of stay in patients with septic shock, supporting its role as a potential component of a multimodal vasopressor strategy. They emphasized the need for larger multicenter studies to confirm these findings.

Dr. Morgenstern’s RAMMBO approach was utilized to analyze this study.

Strengths

• Design: Double-blind RCT with clearly defined intervention and standardized care.
• Clinically meaningful outcomes: Vasopressor duration and LOS are practical metrics for critical care.
• Good safety profile: No significant adverse effects reported.
• Cost-effective: MB is widely available and inexpensive compared to newer agents.
• Pragmatic dosing strategy: Fixed MB dosing avoided toxicity while remaining effective.

Study Limitations

• Single-center design: Limits generalizability to other settings, especially high-resource ICUs.
• Underpowered for mortality and safety outcomes: While mortality trended lower, the study wasn’t powered to assess this definitively. May also be underpowered to detect adverse events.
• Exclusion Criteria Impact: Excluding patients with a high probability of death within 48 hours may have resulted in a study population with a lower severity of illness, potentially affecting the applicability of the findings to more critically ill patients.
• No COVID-19 patients: Excluded due to uncertainties early in the pandemic.
• Possible unblinding: Green urine and methemoglobin monitoring may have partially revealed group allocation.
• No biomarker confirmation: The study did not measure NO or cytokine levels to confirm the proposed mechanism.

The study suggests that early adjunctive methylene blue may reduce the duration of vasopressor support in patients with septic shock. However, due to the study's limitations, including its single-center design, small sample size, and exclusion criteria, these findings should be interpreted with caution. Further large-scale, multi-center RCTs are necessary to confirm the efficacy and safety of methylene blue in septic shock before it can be recommended for routine clinical use.

1. REBELEM: Adjunctive Methylene Blue in Septic Shock?
2. IBCC: Shock and Vasoactive Medications
3. CoreEM: Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial